Discover
AUPH
Aurinia Pharmaceuticals Inc.
15.64
5 x 15.55
1 x 15.75
bid
ask
+
0.39
2.56%
106 @ 04:00 PM
15.65 +0.01 (0.06%)
| Ytd | -1.94% | |
| 1y | 81.44% |
15.16
day range
15.70
8.55
52 week range
19.25
| Open | 15.25 | Prev Close | 15.25 | Low | 15.16 | High | 15.70 | Mkt Cap | 2.01B |
| Vol | 991.19K | Avg Vol | 1.50M | EPS | 0.90 | P/E | 17.38 | Forward P/E | 18.48 |
| Beta | 1.41 | Short Ratio | 5.19 | Inst. Own | 60.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 16.01 | 200-d Avg | 15.00 | 1yr Est | 17.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-07-30 | 2026-06 | 0.21 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | 0.18 | 0.25 | 0.07 | 38.89% |
| 2026-02-26 | 2025-12 | 0.21 | 0.26 | 0.05 | 23.81% |
| 2025-11-04 | 2025-09 | 0.16 | 0.23 | 0.07 | 43.75% |
| 2025-07-31 | 2025-06 | 0.17 | 0.16 | -0.01 | -5.88% |
| 2025-05-12 | 2025-03 | 0.08 | 0.16 | 0.08 | 100.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-12-03 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-11-07 | Jefferies | Upgrade | Hold | Buy |
| 2025-11-05 | RBC Capital | Downgrade | Outperform | Sector Perform |
| 2025-08-01 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-09-16 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-09-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-17 | COLE RYAN | Chief Operating Officer | 116.14K | Stock Award(Grant) |
| 2026-02-26 | DONLEY MATTHEW MAXWELL | Chief Operating Officer | 680.30K | Stock Award(Grant) |
| 2026-02-26 | GREENLEAF PETER S | Chief Executive Officer | 1.84M | Stock Award(Grant) |
| 2024-08-05 | HABIG SCOTT MICHAEL | Officer | 456.34K | Sale |
| 2026-05-17 | HEARNE MICHAEL S. | Chief Financial Officer | 116.14K | Stock Award(Grant) |
| 2024-11-20 | JAYNE DAVID ROLAND WALKER | Director | 56.50K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | TANG CAPITAL MANAGEMENT LLC | 12.23M | 0.00 | 9.51% |
| 2026-03-30 | BlackRock Inc | 7.85M | 0.00 | 6.10% |
| 2026-03-30 | NEA Management Company, LLC | 3.97M | 0.00 | 3.09% |
| 2026-03-30 | Two Sigma Investments LLC | 3.43M | 0.00 | 2.67% |
| 2026-03-30 | Arrowstreet Capital Limited Partnership | 3.28M | 0.00 | 2.55% |
| 2026-03-30 | State Street Corp | 2.53M | 0.00 | 1.97% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-28 | iShares Russell 2000 ETF | 2.85M | 0.00 | 2.22% |
| 2026-03-30 | Fidelity Small Cap Index | 1.17M | 0.00 | 0.91% |
| 2026-05-28 | iShares Russell 2000 Growth ETF | 976.69K | 0.00 | 0.76% |
| 2026-05-28 | iShares Biotechnology ETF | 867.08K | 0.00 | 0.67% |
| 2025-12-30 | Russell 2000 Equity Index Fund B | 750.38K | 0.00 | 0.58% |
| 2026-05-30 | State St Russell Sm/Mid Cp® Indx SL Cl I | 722.20K | 0.00 | 0.56% |